Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07164807 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Methylene Blue Plus Ropivacaine for Post-Hemorrhoidectomy Pain.

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 10, 2025 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
Revised Translation (Academic English): As one of the most prevalent anorectal disorders, mixed hemorrhoids continue to rely on the Milligan-Morgan hemorrhoidectomy as the gold-standard surgical approach. While this technique demonstrates well-established efficacy, managing acute postoperative pain-particularly during the critical 24-72-hour peak pain window-remains a persistent clinical challenge. Recent advancements in multimodal analgesia have highlighted the potential of local nerve blockers, with methylene blue (MB) gaining scientific interest due to its prolonged analgesic properties. This randomized controlled study systematically evaluates the synergistic analgesic effects of gradient concentrations of MB combined with ropivacaine (ROP) following Milligan-Morgan procedures. Therapeutic safety profiles were validated through dual-dimensional monitoring of Visual Analog Scale (VAS) scores and complication rates, aiming to establish evidence-based optimal dosing protocols and refine perioperative pain management strategies.
Trial Details
NCT Number NCT07164807
Lead Sponsor The Affiliated Hospital of Putian University
Conditions
(from sponsor)
Mixed Hemorrhoids, Milligan-Morgan Hemorrhoidectomy, Methylene Blue
Enrollment 177 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov